摘要
目的：观察比较洛铂加紫杉醇与顺铂加紫杉醇联合方案在妇科恶性肿瘤化疗中的不良反应，了解洛铂在妇科肿瘤联合化疗中的不良反应。方法回顾性选取2012年1月至2015年8月收住本院肿瘤内科或妇产科的妇科恶性肿瘤患者60例作为观察对象，其中30例患者接受洛铂加紫杉醇联合化疗3～6个周期，另外30例患者接受顺铂加紫杉醇联合化疗3～5个周期，将其分别对应为洛铂组、顺铂组。参照WHO抗肿瘤药物急性及亚急性毒性反应分度评价标准，对比两组患者在骨髓抑制、肝肾损害、消化道反应、过敏、神经毒性等方面的不良反应。结果洛铂组的患者多见的不良反应为骨髓抑制、脱发，顺铂组的患者多见的不良反应为骨髓抑制、恶心、呕吐、脱发、肾毒性。但两组对比，洛铂组的恶心、呕吐、肾毒性的发生率低于顺铂组，差异有统计学意义（P＜0.05），洛铂组的血小板减少发生率较顺铂组高，但以Ⅰ～Ⅱ度为主，亦有统计学意义（P＜0.05）。两组在其他不良反应方面差异无统计学意义（P＞0.05）。结论紫杉醇联合洛铂或顺铂均是治疗常见妇科恶性肿瘤患者（卵巢癌、宫颈癌、子宫内膜癌）的有效方案，洛铂组的患者血小板减少发生率较顺铂组稍高，但消化道反应、肾毒性、周围神经毒性均较顺铂组低，相对而言，洛铂更有优势。但本临床观察病例数还较少，设计对比的方法、内容简单，且随访时间相对较短，仍尚需进一步扩大研究。
Objective To observe and compare the main side effects of chemotherapy with Lobaplatin plus Paclitaxel or Cisplatin plus Paclitaxel for gynecologic malignancies.Method Sixty advanced gynecological cancer patients admitted to our hospital from January 2012 to August 2015 were selected retrospectively. Among them, 30 patients received 3~6 cycles of chemotherapy with lobaplation plus paclitaxel, which is referred to as lobaplatin group, while others received 3~5 cycles of chemotherapy with cisplatin plus paclitaxel, which is referred to as cisplatin group. According to WHO grading system for acute and sub-acute toxicity of anti-cancer drugs , side effects caused by chemotherapy such as bone marrow suppression, liver and renal toxicity,digestive reaction,allergy,neurotoxicity were compared between two groups of patients.Result Most of the patients in the Lobaplatin group had signs of bone marrow suppression, hair loss, while patients in the Cisplatin group showed signs of bone marrow suppression,nausea, vomiting, hair loss, renal toxicity. Comparative analysis shows that the incidence of nausea, vomiting and renal toxicity in the Lobaplatin group patients was lower than that of the Cispltin group. The difference was statistically significant（P〈0.05）. The incidence of thrombocytopenia（mainly Ⅰ ~ Ⅱgrade） in Lobaplatin group was much higher than that of the Cisplatin group. The difference was also statistically significant（P 〈0.05）. Differences between the two groups in terms of other side effects had no statistically significance（P 〉0.05）. Conclusion Lobaplatin or Cisplatin plus paclitaxel therapy are both valid gynecologic cancer treatment options. The incidence of thrombocytopenia in the Lobaplatin group was much higher than that of the Cisplatin group, while the incidence of gastrointestinal adverse reactions, nephrotoxicity or peripheral neurotoxicity was lower in the Lobaplatin group than that of the Cisplatin group. Obviously, the lobaplation therapy has more advantages. However, it requ
出处
《创伤与急诊电子杂志》
2016年第1期35-39,48,共6页
Journal of Trauma and Emergency(Electronic Version)
关键词
妇科肿瘤
洛铂
顺铂
紫杉醇
联合化疗
不良反应
Gynecologic malignancies
Lobaplatin
Cisplatin
Paclitaxel
Combined chemotherapy
Side effects
